This article is more than 5 years old. Information may no longer be current.

Juvéderm Voluma effects in facial augmentation lasted up to 1 year

Juvéderm Voluma for facial revolumization produced results lasting up to a year in patients with little risk of adverse events, according to recently published study results.

Shannon Humphrey, MD, FRCPC, FAAD, and colleagues, conducted a retrospective chart review of 2,342 patients who had facial augmentation with Juvéderm Voluma (hyaluronic acid 20 mg/mL smooth cohesive filler, Allergan) between Feb. 1, 2009, and Oct. 1, 2014. The midface was the most frequent treatment area. Two weeks after initial treatment, clinical results were reviewed with touch-ups conducted if necessary. Photographs documented before and after treatment.

Shannon Humphrey

There was a total of 11,460 mL of hyaluronic acid filler used in 4,702 treatments during the study period of 68 months, and approximately 50% of patients received two or more treatments. This inferred high satisfaction levels with the results, the researchers wrote.

The results lasted at least 12 months. Adverse events included erythema and bruising, which were primarily limited to transient injection site reactions and resolved within 5 to 7 days. Signs of vascular compromise developed in three patients, which resolved within 2 months after treatment. Late-onset, temporary, nontender nodules lasting 1 to 16 weeks at injection site developed in 21 patients (0.5%). The patients were treated with “conservative measures” that included watchful waiting, hyaluronidase, intralesional corticosteroids, systemic antibiotics and prednisone, and made a complete recovery.

“This robust 20 mg/mL [hyaluronic acid] filler is ideally formulated for facial revolumization and sculpting and can be adapted for more superficial applications by modifying the injection technique and altering viscosity through dilution,” the researchers concluded. “Results are immediate, predictable, entirely reversible, and clinical effects appear to last 12 months or more with little risk or complication to use or downtime.” – By Bruce Thiel

Disclosure: Humphrey reports serving as a consultant, investigator and/or speaker for Allergan. Please see the full study for list of other researchers’ relevant financial disclosures.